New nano-gel to protect children receiving chemotherapy from hearing loss

Curtin researchers will test a new nano-gel they have created to protect children receiving chemotherapy treatment from the common side effect of hearing loss, as part of a new project with Ear Science Institute Australia and supported by funding from the Channel 7 Telethon Trust. Lead researcher Associate Professor Hani Al-Salami, from the Curtin Health Innovation Research Institute (CHIRI) based at Curtin University, said 90 per cent of children survive cancer but about half will have some degree of permanent hearing due to toxic effects of chemotherapy drugs. "There is currently no proven prevention or cure for this hearing loss, so this new research will test the effectiveness of a nano-gel that is injected into the ear before chemotherapy to prevent the possible side effect of cancer treatment among children," Associate Professor Al-Salami said. "The bile acid-based nano-gel has been developed at Curtin by a group of clinicians, pharmaceutical scientists, ENT (ear, nose and throat) surgeons, cochlea physiologists and synthetic chemists using cutting-edge technologies. "Human bile extract is put through specialised systems to produce a gel, which is capable of being injected into the human ear and can potentially protect children from the side effects of chemotherapy, which targets and destroys cancer tissues and can also kill other healthy tissues resulting in problems including hearing loss. Ear Science Institute Australia CEO Sandra Bellekom said it was a very exciting time for ear and hearing medical research in Western Australia.